Literature DB >> 32031570

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Dawei Wang1, Bo Hu1, Chang Hu1, Fangfang Zhu1, Xing Liu1, Jing Zhang1, Binbin Wang1, Hui Xiang1, Zhenshun Cheng2, Yong Xiong3, Yan Zhao4, Yirong Li5, Xinghuan Wang6, Zhiyong Peng1.   

Abstract

Importance: In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of affected patients is limited. Objective: To describe the epidemiological and clinical characteristics of NCIP. Design, Setting, and Participants: Retrospective, single-center case series of the 138 consecutive hospitalized patients with confirmed NCIP at Zhongnan Hospital of Wuhan University in Wuhan, China, from January 1 to January 28, 2020; final date of follow-up was February 3, 2020. Exposures: Documented NCIP. Main Outcomes and Measures: Epidemiological, demographic, clinical, laboratory, radiological, and treatment data were collected and analyzed. Outcomes of critically ill patients and noncritically ill patients were compared. Presumed hospital-related transmission was suspected if a cluster of health professionals or hospitalized patients in the same wards became infected and a possible source of infection could be tracked.
Results: Of 138 hospitalized patients with NCIP, the median age was 56 years (interquartile range, 42-68; range, 22-92 years) and 75 (54.3%) were men. Hospital-associated transmission was suspected as the presumed mechanism of infection for affected health professionals (40 [29%]) and hospitalized patients (17 [12.3%]). Common symptoms included fever (136 [98.6%]), fatigue (96 [69.6%]), and dry cough (82 [59.4%]). Lymphopenia (lymphocyte count, 0.8 × 109/L [interquartile range {IQR}, 0.6-1.1]) occurred in 97 patients (70.3%), prolonged prothrombin time (13.0 seconds [IQR, 12.3-13.7]) in 80 patients (58%), and elevated lactate dehydrogenase (261 U/L [IQR, 182-403]) in 55 patients (39.9%). Chest computed tomographic scans showed bilateral patchy shadows or ground glass opacity in the lungs of all patients. Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]). Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%]). The median time from first symptom to dyspnea was 5.0 days, to hospital admission was 7.0 days, and to ARDS was 8.0 days. Patients treated in the ICU (n = 36), compared with patients not treated in the ICU (n = 102), were older (median age, 66 years vs 51 years), were more likely to have underlying comorbidities (26 [72.2%] vs 38 [37.3%]), and were more likely to have dyspnea (23 [63.9%] vs 20 [19.6%]), and anorexia (24 [66.7%] vs 31 [30.4%]). Of the 36 cases in the ICU, 4 (11.1%) received high-flow oxygen therapy, 15 (41.7%) received noninvasive ventilation, and 17 (47.2%) received invasive ventilation (4 were switched to extracorporeal membrane oxygenation). As of February 3, 47 patients (34.1%) were discharged and 6 died (overall mortality, 4.3%), but the remaining patients are still hospitalized. Among those discharged alive (n = 47), the median hospital stay was 10 days (IQR, 7.0-14.0). Conclusions and Relevance: In this single-center case series of 138 hospitalized patients with confirmed NCIP in Wuhan, China, presumed hospital-related transmission of 2019-nCoV was suspected in 41% of patients, 26% of patients received ICU care, and mortality was 4.3%.

Entities:  

Mesh:

Year:  2020        PMID: 32031570      PMCID: PMC7042881          DOI: 10.1001/jama.2020.1585

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  2000 in total

Review 1.  The complement system in COVID-19: friend and foe?

Authors:  Anuja Java; Anthony J Apicelli; M Kathryn Liszewski; Ariella Coler-Reilly; John P Atkinson; Alfred Hj Kim; Hrishikesh S Kulkarni
Journal:  JCI Insight       Date:  2020-08-06

2.  Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.

Authors:  Xufang Deng; Alexandra C Buckley; Angela Pillatzki; Kelly M Lager; Kay S Faaberg; Susan C Baker
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  Clinical presentations and management of COVID-19 infected children seen in a district health facility in Kambia, northern Sierra Leone.

Authors:  Hammed Hassan Adetola; David Ishola; Muhammed Olanrewaju Afolabi; Joseph Bangura; Isaac Gibril Sesay; Richmonda Pearce; Isaac Garrick; Bomposseh Kamara; Bailah Leigh; Brian Greenwood; Deborah Watson-Jones
Journal:  Pan Afr Med J       Date:  2020-10-27

4.  A chronicle of SARS-CoV-2: Seasonality, environmental fate, transport, inactivation, and antiviral drug resistance.

Authors:  Manish Kumar; Payal Mazumder; Sanjeeb Mohapatra; Alok Kumar Thakur; Kiran Dhangar; Kaling Taki; Santanu Mukherjee; Arbind Kumar Patel; Prosun Bhattacharya; Pranab Mohapatra; Jörg Rinklebe; Masaaki Kitajima; Faisal I Hai; Anwar Khursheed; Hiroaki Furumai; Christian Sonne; Keisuke Kuroda
Journal:  J Hazard Mater       Date:  2020-10-06       Impact factor: 10.588

5.  Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study.

Authors:  Tian-Yuan Xiong; Fang-Yang Huang; Qi Liu; Yong Peng; Yuan-Ning Xu; Jia-Fu Wei; Nian Li; Bei Bai; Jun-Hua Li; Bernard Prendergast; Wei-Min Li; Mao Chen
Journal:  Ann Med       Date:  2020-07-31       Impact factor: 4.709

6.  Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis.

Authors:  Ashish Kumar; Anil Arora; Praveen Sharma; Shrihari Anil Anikhindi; Naresh Bansal; Vikas Singla; Shivam Khare; Abhishyant Srivastava
Journal:  SSRN       Date:  2020-04-21

7.  Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.

Authors:  Juyi Li; Xiufang Wang; Jian Chen; Hongmei Zhang; Aiping Deng
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

Review 8.  Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications.

Authors:  Maria Vega Brizneda; Agam Bansal; Vardhmaan Jain; Samir Kapadia; Lars G Svensson; Venu Menon; Paul Cremer; Grant Reed; Penelope Rampersad; Richard Grimm; Brian P Griffin; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 9.  What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?

Authors:  Yaşar Keskin; Gökhan Koz; Kemal Nas
Journal:  Eurasian J Med       Date:  2021-06

10.  The Pathology of Severe COVID-19-Related Lung Damage.

Authors:  Felix K F Kommoss; Constantin Schwab; Luca Tavernar; Johannes Schreck; Willi L Wagner; Uta Merle; Danny Jonigk; Peter Schirmacher; Thomas Longerich
Journal:  Dtsch Arztebl Int       Date:  2020-07-20       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.